It this study, inhibition of MDM2 increased the sensitivity of resistant HMCLs and primary MM xenograft samples to bortezomib and other anti-myeloma drugs, demonstrating that MDM2 can modulate drug response. Here, MDM2 is linked to plasma cell myeloma.